| Issue | Title | |
| Vol 2005, No 60 (2005) | GlaxoSmithKline Agrees to Buy Biopharmaceutical Company Corixa | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 44 (2004) | GlaxoSmithKline and NeuroSearch to Investigate CNS Diseases | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 71 (2006) | GlaxoSmithKline and Sirna Enter Major RNAi Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 62 (2005) | GlaxoSmithKline and Vitae Sign Hypertension Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 97 (2008) | GlaxoSmithKline Boosts its Infectious Disease Portfolio | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2010, No 10 (2010) | GlaxoSmithKline Expands into China with Nanjing MeiRui Pharma Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 1 (2011) | GlaxoSmithKline Forms US$650 M Epigenetics Alliance with Epizyme | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 80 (2007) | GlaxoSmithKline Further Improves its Biologics Capabilities | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 90 (2007) | GlaxoSmithKline Gains Antibody for Type I Diabetes | Abstract pdf |
| Business Review Editor | ||
| Vol 2022, No 4 (2022) | GlaxoSmithKline Gets Momelotinib with US$1.9 B Sierra Oncology Buyout | Abstract html pdf |
| Sasha Yachu | ||
| Vol 2020, No 7 (2020) | GlaxoSmithKline Partners with CureVac to Develop mRNA-based Vaccines | Abstract pdf html |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2020, No 2 (2020) | GlaxoSmithKline Pays €45 M Upfront to Access Immatics’ Cell Therapy Platform | Abstract html pdf |
| Michelle Liu | ||
| Vol 2012, No 7 (2012) | GlaxoSmithKline Secures Human Genome Sciences Takeover with Sweetened Offer | Abstract |
| Heather Cartwright | ||
| Vol 2020, No 6 (2020) | GlaxoSmithKline Signs US$3 B Synthetic Lethality Alliance with IDEAYA Biosciences | Abstract pdf html |
| Michelle Liu | ||
| Vol 2010, No 5 (2010) | GlaxoSmithKline Strengthens Presence in Emerging Asian Markets | Abstract |
| Taskin Ahmed | ||
| Vol 2009, No 6 (2009) | GlaxoSmithKline to Access Concert’s Deuterium Technology | Abstract |
| Taskin Ahmed | ||
| Vol 2010, No 5 (2010) | Glenmark Inks Two Progressive Deals | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 5 (2011) | Glenmark Pharmaceuticals Out-Licenses Anti-Inflammatory Antibody to Sanofi-aventis | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 75 (2006) | Good Cop:Bad Cop in Negotiations | Abstract html |
| Fintan Walton | ||
| Vol 2003, No 39 (2003) | GPC Biotech AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 79 (2007) | Graffinity Pharmaceuticals GmbH | Abstract |
| Business Review Editor | ||
| Vol 2010, No 6 (2010) | Grifols Buys Talecris to Increase US Share in Plasma Protein Therapies | Abstract |
| Debbie Tranter | ||
| Vol 2016, No 12 (2016) | Grünenthal Bolsters its Pain Pipeline with Thar Acquisition | Abstract html pdf |
| Jawala Prasad | ||
| Vol 2002, No 28 (2002) | Grupo Ferrer Internacional SA | Abstract pdf |
| Business Review Editor | ||
| Vol 2024, No 1 (2024) | GSK Acquires Aiolos Bio for US$1.4 B | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2024, No 11 (2024) | GSK Acquires Chimagen Biosciences’ CMG1A46 for US$300 M Upfront | Abstract pdf html |
| Shweta Gupta & Swati Sharan | ||
| Vol 2003, No 32 (2003) | GSK Acquires Dermatology Products from Elan | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 101 (2008) | GSK Acquires Genelabs to Boost its HCV Pipeline | Abstract html |
| Helen Scrutton | ||
| Vol 2018, No 4 (2018) | GSK Acquires Novartis’ Stake in Consumer Healthcare Joint Venture for US$13 B | Abstract pdf html |
| Subham Nandi | ||
| Vol 2008, No 91 (2008) | GSK Acquires Reliant Pharmaceuticals | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 35 (2003) | GSK and Flamel Announce Licence Agreement | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | GSK and Neose in Vaccine Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2018, No 12 (2018) | GSK and Pfizer Form Consumer Healthcare Joint Venture | Abstract pdf html |
| Michelle Liu | ||
| Vol 2009, No 4 (2009) | GSK and Pfizer Join Forces to Create New HIV Firm | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 81 (2007) | GSK and XenoPort to Collaborate on Late-Stage Compound for RLS and Neuropathic Pain | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 6 (2013) | GSK Brings Next-Generation Vaccine Technology In-House with Okairos Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 4 (2009) | GSK Buys Stiefel Laboratories | Abstract |
| Taskin Ahmed | ||
| Vol 2012, No 8 (2012) | GSK Divests Genericised Brands in Australia to Aspen Pharmacare | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 4 (2012) | GSK Divests its Final Tranche of Non-Core OTC Brands to Aspen Pharmacare | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 94 (2008) | GSK Enters into Sirtuin Field with Latest Acquisition | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2019, No 9 (2019) | GSK Exercises Option for Ionis’ Hepatitis B Programmes | Abstract pdf html |
| Michelle Liu | ||
| Vol 2012, No 3 (2012) | GSK Finds a Buyer in Omega Pharma for its Non-Core OTC Brands in Europe | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 10 (2009) | GSK forms Joint Venture to Tap China’s Vaccine Market | Abstract |
| Taskin Ahmed | ||
| Vol 2023, No 11 (2023) | GSK Gains Rights to Janssen’s Hepatitis B Therapy JNJ-3989 for US$1 B | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2014, No 8 (2014) | GSK Highlights Immuno-Oncology Focus with Adaptimmune Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 2 (2019) | GSK Hopes to Lead New Class of Immunotherapies with Merck KGaA Collaboration | Abstract pdf html |
| Michelle Liu | ||
| Vol 2010, No 2 (2010) | GSK in Lung Drug Deal with Apeiron | Abstract |
| Taskin Ahmed | ||
| Vol 2005, No 64 (2005) | GSK Keeps an Eye on Vaccines Business with Potential ID Biomedical Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 2 (2009) | GSK Licenses Idenix’s HIV Drug | Abstract html |
| Taskin Ahmed | ||
| Vol 2002, No 25 (2002) | GSK licenses oral insulin from Nobex | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | GSK Licenses Phase II Compounds from Exelixis | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 33 (2003) | GSK Licenses Rights to Preclinical HIV Compound | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | GSK Licenses SGLT2-inhibitor from Kissei | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 76 (2006) | GSK Loads up the Potential Milestones from Chemocentryx | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 9 (2010) | GSK Obtains Exclusive Rights to Amicus Therapeutics’ Drug for Fabry Disease | Abstract |
| Editorial Team | ||
| Vol 2009, No 10 (2009) | GSK Opens Rare Diseases Portfolio with Prosensa’s DMD Candidate | Abstract |
| Taskin Ahmed | ||
| Vol 2023, No 10 (2023) | GSK Partners with Zhifei to Boost Shingrix® in China | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2025, No 2 (2025) | GSK Pays US$1.15 B To Acquire IDRx | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2022, No 9 (2022) | GSK Pays US$66 M Upfront for Spero’s Late-Stage Antibiotic | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 12 (2018) | GSK Re-enters Oncology Arena with US$5.1 B Tesaro Acquisition | Abstract pdf html |
| Michelle Liu | ||
| Vol 2008, No 101 (2008) | GSK Seeks Growth in Emerging Markets | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2009, No 10 (2009) | GSK Signs Cancer Deal with SuperGen | Abstract |
| Taskin Ahmed | ||
| Vol 2017, No 7 (2017) | GSK Signs Drug Discovery Deal with AI Company Exscientia | Abstract pdf html |
| Natasha Piper | ||
| Vol 2009, No 7 (2009) | GSK Signs Drug Pact with Chroma Therapeutics | Abstract |
| Taskin Ahmed | ||
| Vol 2024, No 8 (2024) | GSK Signs Immunology and Respiratory Collaboration Deal with Flagship Pioneering | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2024, No 12 (2024) | GSK Signs US$1 B+ Partnerships with Duality Biologics and Rgenta Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2022, No 8 (2022) | GSK Signs US$1.4 B ADC Option Deal with Mersana | Abstract html pdf |
| Lucy Haggerty | ||
| Vol 2023, No 10 (2023) | GSK Signs US$1.5 B ADC Licensing Pact with Hansoh Pharma | Abstract pdf html |
| Lalit Mishra | ||
| Vol 2025, No 4 (2025) | GSK Signs US$2.7B+ Licensing Pact with ABL Bio for Neurodegenerative Diseases | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2012, No 6 (2012) | GSK Strengthens its Dermatology Business with Acquisition of Basilea’s Toctino® | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 5 (2012) | GSK to Acquire Full Control of its Proteomics Partner Cellzome | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 56 (2005) | GSK Transfers Levitra® Co-Promotion Rights Back to Bayer | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 6 (2012) | GSK’s Stiefel Laboratories Acquires Welichem Biotech’s Mid-Stage Psoriasis and Atopic Dermatitis Drug | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 67 (2006) | Guidant's Takeover: The Pace Quickens | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Guilford Licenses Neurological Drugs to Pfizer | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | GW Pharma and Bayer in Cannabinoid Deal | Abstract |
| Business Review Editor | ||
| Vol 2003, No 38 (2003) | GW Pharmaceuticals plc | Abstract |
| Business Review Editor | ||
| Vol 2002, No 26 (2002) | H. Lundbeck AS | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | H5N1: Preparing for the Worst | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 1 (2013) | Halozyme’s Enhanze™ Technology Gains Much-Needed Boost with Pfizer Collaboration | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 70 (2006) | Hana Biosciences Licenses Cancer Products from Inex Pharmaceuticals | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 10 (2016) | Hanmi Partners RAF inhibitor HM95573 with Genentech in a deal worth US$910 M | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2021, No 11 (2021) | Hansoh Pharma Signs US$1.3 B RNAi Collaboration with Silence Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2019, No 10 (2019) | Hansoh Pharmaceutical Signs US$1.5 B AI Drug Discovery Collaboration with Atomwise | Abstract html pdf |
| Anupama Sharma & Michelle Liu | ||
| Vol 2011, No 7 (2011) | Hardball | Abstract jpg |
| Clive Goddard | ||
| Vol 2021, No 4 (2021) | Helsinn Boosts Oncology Portfolio with BridgeBio’s Infigratinib | Abstract pdf html |
| Michelle Liu | ||
| Vol 2006, No 67 (2006) | Hemispherx Biopharma Signs the Latest in a Series of R&D Deals for Flu Therapeutics in 2005 | Abstract pdf |
| Business Review Editor | ||
| Vol 2011, No 6 (2011) | Heptares Therapeutics and AstraZeneca to Research GPCR Drug Targets | Abstract |
| Heather Cartwright | ||
| Vol 2006, No 73 (2006) | HGS Spin-off Licenses Technology from Parent Company | Abstract |
| Business Review Editor | ||
| Vol 2014, No 6 (2014) | Hikma Builds Presence in US Injectables Market via Boehringer Ingelheim Asset Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 10 (2010) | Hikma Pharmaceuticals Reinforces its Global Portfolio with Purchase of Baxter Healthcare’s US Generic Injectables Business | Abstract |
| Heather Cartwright | ||
| Vol 2007, No 81 (2007) | Hikma Set to Enter Oncology Market with Acquisition of ribosepharm | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 69 (2006) | Hirulog (bivalirudin) | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 7 (2009) | Hisamitsu’s Expansion in the US | Abstract |
| Taskin Ahmed | ||
| Vol 2021, No 5 (2021) | Hologic Enters Acute Care Market with US$795 M Mobidiag Acquisition | Abstract pdf html |
| Debadrita Paul & Michelle Liu | ||
| Vol 2022, No 11 (2022) | Hookipa Pharma signs US$958 M Deal with Roche to develop HB-700 for KRAS-mutated Cancers | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2021, No 2 (2021) | Horizon Continues to Build Rare Disease Pipeline with US$3.05 B Viela Buy | Abstract pdf html |
| Michelle Liu | ||
| Vol 2016, No 9 (2016) | Horizon Pharma Bolsters Orphan Drug Portfolio with US$800 M Purchase of Raptor Pharmaceuticals | Abstract pdf html |
| Jawala Prasad | ||
| Vol 2014, No 4 (2014) | Horizon Pharma Looks to Tax Efficiency with Acquisition of Ireland’s Vidara Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2003, No 34 (2003) | Hormos Medical and Solvay Collaborate on Women’s Health R&D | Abstract pdf |
| Business Review Editor | ||
| 1201 - 1300 of 2581 Items | << < 8 9 10 11 12 13 14 15 16 17 > >> | |